Scott C Ritchie, Henry J Taylor, Yujian Liang, Hasanga D Manikpurage, Lisa Pennells, Carles Foguet, Gad Abraham, Joel T Gibson, Xilin Jiang, Yang Liu, Yu Xu, Lois G Kim, Anubha Mahajan, Mark I McCarthy, Stephen Kaptoge, Samuel A Lambert, Angela Wood, Xueling Sim, Francis S Collins, Joshua C Denny, John Danesh, Adam S Butterworth, Emanuele Di Angelantonio, Michael Inouye
{"title":"利用多因素多基因风险评分综合预测 2 型糖尿病的临床风险。","authors":"Scott C Ritchie, Henry J Taylor, Yujian Liang, Hasanga D Manikpurage, Lisa Pennells, Carles Foguet, Gad Abraham, Joel T Gibson, Xilin Jiang, Yang Liu, Yu Xu, Lois G Kim, Anubha Mahajan, Mark I McCarthy, Stephen Kaptoge, Samuel A Lambert, Angela Wood, Xueling Sim, Francis S Collins, Joshua C Denny, John Danesh, Adam S Butterworth, Emanuele Di Angelantonio, Michael Inouye","doi":"10.1101/2024.08.22.24312440","DOIUrl":null,"url":null,"abstract":"<p><p>Combining information from multiple GWASs for a disease and its risk factors has proven a powerful approach for development of polygenic risk scores (PRSs). This may be particularly useful for type 2 diabetes (T2D), a highly polygenic and heterogeneous disease where the additional predictive value of a PRS is unclear. Here, we use a meta-scoring approach to develop a metaPRS for T2D that incorporated genome-wide associations from both European and non-European genetic ancestries and T2D risk factors. We evaluated the performance of this metaPRS and benchmarked it against existing genome-wide PRS in 620,059 participants and 50,572 T2D cases amongst six diverse genetic ancestries from UK Biobank, INTERVAL, the All of Us Research Program, and the Singapore Multi-Ethnic Cohort. We show that our metaPRS was the most powerful PRS for predicting T2D in European population-based cohorts and had comparable performance to the top ancestry-specific PRS, highlighting its transferability. In UK Biobank, we show the metaPRS had stronger predictive power for 10-year risk than all individual risk factors apart from BMI and biomarkers of dysglycemia. The metaPRS modestly improved T2D risk stratification of QDiabetes risk scores for 10-year risk prediction, particularly when prioritising individuals for blood tests of dysglycemia. Overall, we present a highly predictive and transferrable PRS for T2D and demonstrate that the potential for PRS to incrementally improve T2D risk prediction when incorporated into UK guideline-recommended screening and risk prediction with a clinical risk score.</p>","PeriodicalId":94281,"journal":{"name":"medRxiv : the preprint server for health sciences","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11370520/pdf/","citationCount":"0","resultStr":"{\"title\":\"Integrated clinical risk prediction of type 2 diabetes with a multifactorial polygenic risk score.\",\"authors\":\"Scott C Ritchie, Henry J Taylor, Yujian Liang, Hasanga D Manikpurage, Lisa Pennells, Carles Foguet, Gad Abraham, Joel T Gibson, Xilin Jiang, Yang Liu, Yu Xu, Lois G Kim, Anubha Mahajan, Mark I McCarthy, Stephen Kaptoge, Samuel A Lambert, Angela Wood, Xueling Sim, Francis S Collins, Joshua C Denny, John Danesh, Adam S Butterworth, Emanuele Di Angelantonio, Michael Inouye\",\"doi\":\"10.1101/2024.08.22.24312440\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Combining information from multiple GWASs for a disease and its risk factors has proven a powerful approach for development of polygenic risk scores (PRSs). This may be particularly useful for type 2 diabetes (T2D), a highly polygenic and heterogeneous disease where the additional predictive value of a PRS is unclear. Here, we use a meta-scoring approach to develop a metaPRS for T2D that incorporated genome-wide associations from both European and non-European genetic ancestries and T2D risk factors. We evaluated the performance of this metaPRS and benchmarked it against existing genome-wide PRS in 620,059 participants and 50,572 T2D cases amongst six diverse genetic ancestries from UK Biobank, INTERVAL, the All of Us Research Program, and the Singapore Multi-Ethnic Cohort. We show that our metaPRS was the most powerful PRS for predicting T2D in European population-based cohorts and had comparable performance to the top ancestry-specific PRS, highlighting its transferability. In UK Biobank, we show the metaPRS had stronger predictive power for 10-year risk than all individual risk factors apart from BMI and biomarkers of dysglycemia. The metaPRS modestly improved T2D risk stratification of QDiabetes risk scores for 10-year risk prediction, particularly when prioritising individuals for blood tests of dysglycemia. Overall, we present a highly predictive and transferrable PRS for T2D and demonstrate that the potential for PRS to incrementally improve T2D risk prediction when incorporated into UK guideline-recommended screening and risk prediction with a clinical risk score.</p>\",\"PeriodicalId\":94281,\"journal\":{\"name\":\"medRxiv : the preprint server for health sciences\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11370520/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"medRxiv : the preprint server for health sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1101/2024.08.22.24312440\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv : the preprint server for health sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2024.08.22.24312440","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
事实证明,将来自多个基因组研究的信息与一种疾病及其风险因素结合起来,是开发多基因风险评分(PRSs)的有效方法。这对 2 型糖尿病(T2D)可能特别有用,因为 T2D 是一种高度多基因和异质性的疾病,PRS 的额外预测价值尚不明确。在这里,我们使用元评分方法开发了一种针对 T2D 的元 PRS,其中纳入了欧洲和非欧洲遗传血统与 T2D 风险因素之间的全基因组关联。我们在英国生物库、INTERVAL、All of Us Research Program 和新加坡多种族队列的 620,059 名参与者和 50,572 个 T2D 病例中评估了该元 PRS 的性能,并将其与现有的全基因组 PRS 进行了比较。我们的研究表明,在欧洲人群队列中,我们的元PRS是预测T2D最有力的PRS,其性能可媲美最高的特定祖先PRS,这突出表明了它的可移植性。在英国生物数据库中,我们发现元PRS对10年风险的预测能力强于除体重指数和血糖异常生物标志物以外的所有个体风险因素。元PRS适度改善了QDiabetes风险评分对10年风险预测的T2D风险分层,尤其是在优先考虑进行血糖异常血液检测时。总之,我们提出了一种对 T2D 具有高度预测性和可转移性的 PRS,并证明了当 PRS 纳入英国指南推荐的筛查和临床风险评分的风险预测时,有可能逐步改善 T2D 风险预测。
Integrated clinical risk prediction of type 2 diabetes with a multifactorial polygenic risk score.
Combining information from multiple GWASs for a disease and its risk factors has proven a powerful approach for development of polygenic risk scores (PRSs). This may be particularly useful for type 2 diabetes (T2D), a highly polygenic and heterogeneous disease where the additional predictive value of a PRS is unclear. Here, we use a meta-scoring approach to develop a metaPRS for T2D that incorporated genome-wide associations from both European and non-European genetic ancestries and T2D risk factors. We evaluated the performance of this metaPRS and benchmarked it against existing genome-wide PRS in 620,059 participants and 50,572 T2D cases amongst six diverse genetic ancestries from UK Biobank, INTERVAL, the All of Us Research Program, and the Singapore Multi-Ethnic Cohort. We show that our metaPRS was the most powerful PRS for predicting T2D in European population-based cohorts and had comparable performance to the top ancestry-specific PRS, highlighting its transferability. In UK Biobank, we show the metaPRS had stronger predictive power for 10-year risk than all individual risk factors apart from BMI and biomarkers of dysglycemia. The metaPRS modestly improved T2D risk stratification of QDiabetes risk scores for 10-year risk prediction, particularly when prioritising individuals for blood tests of dysglycemia. Overall, we present a highly predictive and transferrable PRS for T2D and demonstrate that the potential for PRS to incrementally improve T2D risk prediction when incorporated into UK guideline-recommended screening and risk prediction with a clinical risk score.